FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(31 sites)

United States

Stanford Healthcare, Palo Alto, California

Clinical Translational Research Site, Miami, Florida

Tampa General Medical Group, Tampa, Florida

Rush University Medical Center, Chicago, Illinois

Mercy Medical Center, Baltimore, Maryland

Beth Israel Deaconess Medical Center, Boston, Massachusetts

UMass Memorial Medical Center, Worcester, Massachusetts

Henry Ford Health System, Detroit, Michigan

Mayo Clinic, Rochester, Minnesota

Rutgers-New Jersey Medical School, Newark, New Jersey

Northwell Health Center for Liver Disease and Transplantation, Manhasset, New York

Columbia University Medical Center/New York Presbyterian Hospital, New York, New York

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Vanderbilt Digestive Disease Center, Nashville, Tennessee

The Liver Institute at Methodist Dallas Medical Center, Dallas, Texas

Parkland Health and Hospital System, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

Baylor College of Medicine, Houston, Texas

University of Utah Hospital, Salt Lake City, Utah

VCU Health Clinical Research Services Unit, Richmond, Virginia

France

CHU Angers, Angers, France

Hopital Beaujon, Clichy

Hopital Claude Huriez, Lille

Hopital Pitie Salpetriere, Paris

Hopital Rangueil, Toulouse

United Kingdom

Cambridge University NHS Foundation Trust, Cambridge

Royal Free Hospital, London

Imperial College Healthcare NHS Trust, London

King's College Hospital, London

University Hospitals Plymouth NHS Trust, Plymouth